Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

• Status: Completed
• Trial end date: 2018-02-23
• Target enrollment: 0
• Participant gender: All

Summary

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Menlo Therapeutics Inc.; Vyne Therapeutics Inc.
• Treatments: Serlopitant

Criteria

Inclusion Criteria:

• Male or female, age 13 years or older

• Pruritus prior to and during the initial screening period

• Diagnosis of atopic dermatitis

• Judged to be in good health in the investigator's opinion

Exclusion Criteria:

• Prior treatment with study drug or similar drug

• Pruritus due to another reason besides atopic dermatitis

• Presence of any medical condition or disability that could interfere with study

• History of hypersensitivity to serlopitant or any of its components

• Currently pregnant or male partner of pregnant female

• Females of childbearing potential who are unable or unwilling to use adequate contraception or who are breast feeding